Trading Ideas

…read more […]

Europe’s Just Eat Takeaway and Grubhub are finalizing an all-stock deal in which Just Eat Takeaway would pay a small premium to $58 per Grubhub share, according to CNBC. Uber shares tumbled on the news its deal with Grubhub may be in jeopardy. Yahoo Finance’s The Final Round panel breaks down the details.
…read more […]

A sobering stat supplied by Federal Reserve chief Jerome Powell at his latest policy press conference. …read more […]

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […] …read more […]

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […] …read more […]

The central bank sees no rate hikes through 2022. Here’s what that means for mortgages. …read more […]

Nuveen Head of Fixed Income Strategy Tony Rodriguez joins Yahoo Finance’s Heidi Chung to discuss the Fed’s decision to hold rates steady at near-zero levels. …read more […]

Like a puppy chasing its tail, some new investors often chase ‘the next big thing’, even if that means buying ‘story… …read more […]

In this article we will check out the progression of hedge fund sentiment towards Sorrentto Therapeutics Inc (NASDAQ:SRNE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […] …read more […]

The government is stepping up its efforts to fund vaccine studies and production for at least three of five frontrunner candidates — something that Dr. Anthony Fauci told Yahoo Finance will be worth its weight in gold in the long run. …read more […]

There are hundreds of stocks that pay dividends. Some have high yields, while others pay little-to-nothing to shareholders. Although, dividend yields alone don’t help us determine the best dividend stocks to buy.
When buying income stocks, it’s important to look at both share price and the underlying value. The following Warren Buffett quote sums it up…
Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.
With socks, it’s pretty easy to determine the quality relative to price. But when it comes to stocks, that’s the tough part. So, the best investors take a close look …read more […]

Sorrento Therapeutics’ (SRNE) competitors might be further down the line with their COVID-19 programs, but H.C. Wainwright analyst Ram Selvaraju highlights two separate routes the biotech could take to bring possible treatments and/or preventative therapies to market.Last week, Sorrento disclosed that in preclinical trials, the company’s monoclonal antibody (MaB), STI-4938, code named COVIDTRAP, inhibited SARS-CoV-2 viral infection in vitro.The data showed that STI-4938, an ACE2-Fc decoy protein, binds solidly to the SARS-CoV-2 virus spike protein, and is able to stop the virus from infecting the respiratory cells (specifically, in African green monkey kidney epithelial cells).Sorrento has another antibody in development, …read more […]

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […] …read more […]

Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned -19.6% in the same quarter. You should check out Miller […] …read more […]

This lawsuit focuses on 80 topical generic drugs, including creams, gels and ointments, which have billions in dollars of U.S. sales. It accuses Novartis unit Sandoz, Teva generic unit Actavis, Mylan Inc, Pfizer and other companies of breaking antitrust law by dividing up markets and rigging bids, according to statements from the attorneys general. …read more […]